Blueprint Medicines Corp: key financial figures for fiscal year 2024 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:
- Revenue (FY2024)
- $508.8M
- Net Income/Loss (FY2024)
- -$67.1M
- Total Assets (FY2024)
- $1.2B
- Total Equity (FY2024)
- $298.7M
- Cash Flows from Operating Activities (FY2024)
- -$192.6M
Source: Blueprint Medicines Corp 10-K filing (FY2024). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.
